Compare Quest Diagnostics Inc (DGX) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs L3Harris Technologies Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while L3Harris Technologies Inc trades at $236.97 (market cap $44.12B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and L3Harris Technologies Inc for 56 Days on average.
| DGX | LHX | |
|---|---|---|
Market Cap | $25.48B | $44.12B |
Volume | 941,866 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $247.45 | $378.48 |
52-Week Low | $173.49 | $233.63 |
Typical Hold Time | 56 Days | 56 Days |
Enterprise Value | $31.23B | $54.56B |
Dividend Yield | 1.49% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
LHX trades at $236.92, up 1.41% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 7.34% net income margin. The company secured major defense contracts totaling over $10.7 billion recently, while technical indicators show bearish momentum despite positive analyst sentiment with a $340 consensus price target representing 44% upside potential.
LHX presents a compelling investment case with robust defense contract wins and improving profitability, though investors face headwinds from multiple law firm investigations and bearish technical signals. The stock's current valuation appears reasonable with a P/E of 23.93, but legal uncertainties require careful monitoring alongside the company's strong defense sector positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
